Hired and Retired: High profile exits to biotech
(Image: Getty/Tomertu)
The numbers of high profile executives departing large pharma companies this month again emphasised the draw of working in the biotech industry.
Only shortly after pulling off a major coup by appointing a new head of oncology, Novartis was dealt a blow as they left for pastures new.
Fellow Swiss company, Roche, also had departures from within its ranks one of which was to help lead a newly acquired company.
